Mesenchymal stromal cell therapy for liver diseases

Mohammed Alfaifi, Young Woo Eom, Philip N. Newsome, Soon Koo Baik

Research output: Contribution to journalArticlepeer-review

57 Citations (Scopus)
208 Downloads (Pure)


The therapeutic potential of mesenchymal stromal cells (MSCs) in the treatment of liver fibrosis is predominantly based on their immunosuppressive properties, and their ability to secrete various trophic factors. This potential has been investigated in clinical and preclinical studies. Although the therapeutic mechanisms of MSC transplantation are still not fully characterised, accumulating evidence has revealed that various trophic factors secreted by MSCs play key therapeutic roles in regeneration by alleviating inflammation, apoptosis, and fibrosis as well as stimulating angiogenesis and tissue regeneration in damaged liver. In this review, we summarise the safety, efficacy, potential transplantation routes and therapeutic effects of MSCs in patients with liver fibrosis. We also discuss some of the key strategies to enhance the functionality of MSCs, which include sorting and/or priming with factors such as cytokines, as well as genetic engineering.
Original languageEnglish
JournalJournal of Hepatology
Early online date7 Feb 2018
Publication statusPublished - Feb 2018


  • mesenchymal stromal cell
  • liver disease
  • enrichment
  • priming
  • genetic engineering


Dive into the research topics of 'Mesenchymal stromal cell therapy for liver diseases'. Together they form a unique fingerprint.

Cite this